AdventHealth

adventhealth.com

Total trials

167

Active

56

Phase 3

2

Total enrollment

22,161

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Methadone1
Suzetrigine1
18F-rhPSMA-7.31
SGLT-2 inhibitor1
Glucagon3
Darolutamide1
Relugolix1
SGLT2 inhibitor1

Next readouts

  • 2017-01-13
  • 2018-02-14
  • 2024-07-23
  • 2026-06
  • 2026-07-01
  • 2027-09-05
  • 2028-04
  • 2030-04

Top conditions

  • Obesity12
  • Pancreatic Cancer8
  • Type 2 Diabetes8
  • Stress6
  • Diabetes6
  • Pancreatic Neoplasms5
  • Type 1 Diabetes4
  • Burnout4

Frequently asked questions about AdventHealth

How many clinical trials does AdventHealth have on ClinicalTrials.gov?
AdventHealth is listed as the lead sponsor on 167 clinical trials in ClinicalTrials.gov, 56 of which are currently active (recruiting, enrolling, or ongoing).
How many of AdventHealth's trials are in Phase 3?
2 of AdventHealth's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does AdventHealth focus on?
AdventHealth's most-studied conditions on ClinicalTrials.gov are Obesity, Pancreatic Cancer, Type 2 Diabetes, Stress, Diabetes.
When are AdventHealth's next clinical trial readouts?
AdventHealth has 8 upcoming primary-completion readouts tracked here; the soonest is “To Determine Tolerability to Glucagon Infusion in Obese Subjects”, expected around 2017-01-13.